NB-UVB plus oral Polypodium leucotomos extract display higher efficacy than NB-UVB alone in patients with vitiligo.
- 2021-02-05
- Dermatologic therapy 34(2)
- Alessia Pacifico
- Giovanni Damiani
- Paolo Iacovelli
- Rosalynn R Z Conic
- Salvador Gonzalez
- Aldo Morrone
- PubMed: 33433041
- DOI: 10.1111/dth.14776
Study Design
- Type
- Randomized Controlled Trial (RCT)
- Sample size
- n = 21
- Population
- 44 patients with generalized vitiligo
- Methods
- randomized, prospective, placebo controlled study; combined treatment with NB-UVB phototherapy and 480 mg oral PL twice daily vs NB-UVB phototherapy combined with placebo
- Blinding
- Double-blind
- Duration
- 6 months
- Funding
- Unclear
Polypodium leucotomos displayed a synergic effect with NB-UVB in psoriasis, but its application on vitiligo remains understudied. The aim of this study was to investigate whether oral supplementation with leaves extract of Polypodium leucotomos (PL) improves narrow band (NB) UVB phototherapy-induced repigmentation. Forty-four patients with generalized vitiligo were enrolled in this randomized, prospective, placebo controlled study. Twenty-three patients were randomly selected to receive combined treatment with NB-UVB phototherapy and 480 mg oral PL twice daily while 21 patients received NB-UVB phototherapy combined with placebo. All subjects were treated with NB-UVB twice weekly for 6 months. Our results demonstrated that oral PL combined with NB-UVB improved repigmentation as well as increased the response rate compared with patients treated with NB-UVB alone (47.8% vs 22%). Our study suggests that oral supplementation of PL and NB-UVB phototherapy enhance the extent of repigmentation.
Research Insights
Our results demonstrated that oral PL combined with NB-UVB improved repigmentation as well as increased the response rate compared with patients treated with NB-UVB alone (47.8% vs 22%).
- Effect
- Beneficial
- Effect size
- Moderate
- Dose
- 480 mg twice daily
oral PL combined with NB-UVB improved repigmentation as well as increased the response rate compared with patients treated with NB-UVB alone (47.8% vs 22%).
- Effect
- Beneficial
- Effect size
- Large
- Dose
- 480 mg twice daily